Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

被引：0
|
作者：
Lewis, Ariane
Galetta, Steven
机构：
来源：
NEUROLOGY | 2019年 / 92卷 / 11期
关键词：
D O I：
10.1212/WNL.0000000000007082
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study, Bar-Or et al. demonstrated a significant reduction in the number of new brain lesions in patients who were given ofatumumab compared with those who received placebo. However, Dr. Kearney notes that comparing ofatumumab to placebo, rather than a disease-modifying therapy, could have artificially inflated the benefit of ofatumumab.
引用
收藏
页码：542 / 542
页数：1
相关论文
共 50 条
  • [1] Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
    Bar-Or, Amit
    Grove, Richard A.
    Austin, Daren J.
    Tolson, Jerry M.
    VanMeter, Susan A.
    Lewis, Eric W.
    Derosier, Frederick J.
    Lopez, Monica C.
    Kavanagh, Sarah T.
    Miller, Aaron E.
    Sorensen, Per S.
    [J]. NEUROLOGY, 2018, 90 (20) : E1805 - E1814
  • [2] Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Bar-Or, Amit
    Grove, Richard A.
    Tolson, Jerry M.
    Derosier, Frederick J.
    Lopez, Monica C.
    Kavanagh, Sarah T.
    Miller, Aaron E.
    [J]. NEUROLOGY, 2019, 92 (11) : 543 - 543
  • [3] Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Kearney, Hugh
    [J]. NEUROLOGY, 2019, 92 (11) : 542 - 543
  • [4] Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
    Onder, Halil
    [J]. TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (02) : 105 - 106
  • [5] Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study (vol 90, e1805, 2018)
    [J]. NEUROLOGY, 2018, 91 (11) : 538 - 538
  • [6] Follow-up data from the Mirror study: a dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis
    Sorenson, P. S.
    Kavanagh, S. T.
    Austin, D. J.
    Grove, R. A.
    Lopez, M. C.
    Tolson, J. M.
    Van Meter, S. A.
    Bar-Or, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 88 - 88
  • [7] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    [J]. NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [8] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [9] Lower drug levels in proportion of patients with relapsing-remitting multiple sclerosis on subcutaneous natalizumab
    Toorop, A.
    Rispens, T.
    Nielsen, J.
    Sinnige, L.
    van Dijk, G.
    Uitdehaag, B.
    van Kempen, Z.
    Killestein, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 993 - 993
  • [10] Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
    Bhan, Virender
    Clift, Fraser
    Baharnoori, Moogeh
    Thomas, Kimberly
    Patel, Barkha P.
    Blanchette, Francois
    Adlard, Nicholas
    Vudumula, Umakanth
    Gudala, Kapil
    Dutta, Nikkita
    Grima, Daniel
    Mouallif, Soukaina
    Farhane, Fatine
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (09)
12345